Page last updated: 2024-12-06
6-pentylpyrone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 33960 |
| CHEMBL ID | 503899 |
| CHEBI ID | 66729 |
| SCHEMBL ID | 968257 |
| MeSH ID | M0052968 |
Synonyms (55)
| Synonym |
|---|
| AKOS015839660 |
| 2h-pyran-2-one, 6-pentyl- |
| 6-amyl-.alpha.-pyrone |
| NCI60_041518 |
| 5-hydroxy-2,4-decadienoic acid gamma-lactone |
| 27593-23-3 |
| 6-amyl-alpha-pyrone |
| nsc-721361 |
| nsc721361 |
| 6-amyl-alpha-pyrone, >=96%, fg |
| 6-pentyl-2h-pyran-2-one |
| 6-amyl-2-pyrone |
| 6-pentyl-2-pyrone |
| 6-pentylpyran-2-one |
| CHEMBL503899 |
| chebi:66729 , |
| 6-pentyl-pyran-2-one |
| NCGC00256764-01 |
| tox21_302570 |
| dtxsid0047589 , |
| dtxcid8027589 |
| cas-27593-23-3 |
| 6-n-pentyl-alpha-pyrone |
| unii-8jtw8hl4pj |
| fema no. 3696 |
| einecs 248-552-3 |
| nsc 721361 |
| 5-hydroxy-2,4-decadienoic acid delta-lactone |
| 6-pentyl-alpha-pyrone |
| 8jtw8hl4pj , |
| 5-hydroxy-2,4-decadienoic acid .delta.-lactone [fhfi] |
| 2,4-decadienoic acid, 5-hydroxy-3-methyl-, .delta.-lactone |
| 5-hydroxy-2,4-decadienoic acid .delta.-lactone |
| FT-0620947 |
| mfcd00047551 |
| SCHEMBL968257 |
| 6-pentyl-.alpha.-pyrone |
| pyran-2-one, 6-pentyl- |
| MAUFTTLGOUBZNA-UHFFFAOYSA-N |
| 6-n-amyl .alpha.-pyrone |
| .alpha.-pyrone, 6-pentyl |
| 2-pyrone, 6-pentyl |
| 6-amyl-a-pyrone |
| AS-58448 |
| 2,4-decadien-5-olide |
| 6-n-pentyl-2h-pyran-2-one |
| 6-amyl-alpha -pyrone |
| 6-pentyl-a-pyrone |
| 6-pentyl-alpha -pyrone |
| alpha -pyrone, 6-pentyl |
| 6-n-amyl alpha -pyrone |
| fema 3696 |
| 5-hydroxy-2,4-decadienoic acid d-lactone |
| Q27135350 |
| T70705 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| 2-pyranones | A pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 21.8724 | 0.0002 | 21.2231 | 8,912.5098 | AID743035 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 25.0321 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.5357 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 8.7076 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 19.3312 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1870976 | Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay | 2022 | Journal of natural products, 08-26, Volume: 85, Issue:8 | Syzysamalactone, an Unusual 11-Carbon δ-Lactone Derivative from the Fresh Ripe Fruits of |
| AID379501 | Antimicrobial activity against Botrytis cinerea by spore germination assay | 1999 | Journal of natural products, May, Volume: 62, Issue:5 | Biotransformation of the trichoderma metabolite 6-n-pentyl-2H-pyran-2-one (6PAP) by selected fungal isolates |
| AID377992 | Growth inhibition of etiolated wheat coleoptiles at 1000 uM relative to control | 1999 | Journal of natural products, Jan, Volume: 62, Issue:1 | Koninginin G, a new metabolite from trichoderma aureoviride |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||